Gastrointestinal tolerability of meloxicam and piroxicam: a double‐blind placebo‐controlled study
- 1 August 1998
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 46 (2), 133-137
- https://doi.org/10.1046/j.1365-2125.1998.00761.x
Abstract
Aims The aim of the study was to compare the effects of meloxicam and piroxicam on the gastroduodenal mucosa in healthy adults. Methods Forty-four healthy volunteers were given a 28 day course of either meloxicam 15 mg, piroxicam 20 mg or placebo. Damage to the oesophageal, gastric and duodenal mucosa was assessed, mucosal blood flow (MBF) measured at endoscopy and biopsies taken for prostaglandin content and microscopic assessment of damage before NSAID administration and during days 1, 7 and 28 of continued intake. Results Maximal macroscopic gastric mucosal damage (median grade+IQR) occurred within 24 h of piroxicam administration, the damage score increasing from 0 to 2.5 (0–3) (P=0.02) at day 1 before falling to 2.0 (0–2) at day 7 and 0 (0–1) at day 28 with resolution of damage observed in six out of the seven subjects who sustained acute injury. No significant macroscopic gastric damage occurred in either of the two other groups although some minor damage was observed in seven subjects taking placebo and five taking meloxicam. There was a trend towards piroxicam causing more acute gastric damage than meloxicam (P=0.06). Baseline antral, body and duodenal MBF were similar in all three groups. No significant changes occurred in any of the groups on any of the visits. There were also no changes in gastric mucosal prostaglandin content in any group. Conclusions These observations suggest that meloxicam causes little acute damage to the upper gastrointestinal tract and piroxicam causes some acute gastric injury but such damage resolves in most subjects by 28 days.Keywords
This publication has 19 references indexed in Scilit:
- Gastric mucosal injury and adaptation to oral and rectal administration of naproxenAlimentary Pharmacology & Therapeutics, 1996
- Mucosal adaptation to aspirin induced gastric damage in humans. Studies on blood flow, gastric mucosal growth, and neutrophil activation.Gut, 1994
- Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugsGastroenterology, 1993
- Adaptation of rat gastric mucosa to repeated doses of non-salicylate non-steroidal anti-inflammatory drugsJournal of Gastroenterology and Hepatology, 1992
- Mucosal adaptation to indomethacin induced gastric damage in man--studies on morphology, blood flow, and prostaglandin E2 metabolism.Gut, 1992
- Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory DrugsAnnals of Internal Medicine, 1991
- Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing.Proceedings of the National Academy of Sciences, 1991
- Human gastric perfusion: Evidence for non-uniformity of blood flowBritish Journal of Surgery, 1988
- Prostaglandins and the gastrointestinal mucosa: Are they important in its function, disease, or treatment?Gastroenterology, 1985
- Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like DrugsNature New Biology, 1971